Published in Clin Breast Cancer on April 01, 2005
Research subject enrollment by primary care pediatricians using an electronic health record. AMIA Annu Symp Proc (2007) 1.27
A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist (2012) 1.12
Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients' relational autonomy. Support Care Cancer (2015) 1.12
Improving awareness of cancer clinical trials among Hispanic patients and families: audience segmentation decisions for a media intervention. J Health Commun (2013) 1.06
The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial. Psychooncology (2012) 1.00
Factors influencing the participation of gastroenterologists and hepatologists in clinical research. BMC Health Serv Res (2008) 0.98
Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study. Patient Educ Couns (2014) 0.97
Enrollment onto breast cancer therapeutic clinical trials: a tertiary cancer center experience. Appl Nurs Res (2013) 0.97
Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: a mediational model. Med Decis Making (2013) 0.85
Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. Eur J Cancer Care (Engl) (2014) 0.85
Assessment of perceived cost to the patient and other barriers to clinical trial participation. J Oncol Pract (2011) 0.84
Incentives and barriers to neurological clinical research participation. Clin Investig (Lond) (2011) 0.78
Barriers and facilitators to recruitment to a culturally-based dietary intervention among urban Hispanic breast cancer survivors. J Racial Ethn Health Disparities (2014) 0.75
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. BMC Health Serv Res (2012) 0.75
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries. Lancet (2010) 3.82
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol (2009) 2.61
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med (2007) 2.30
Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg (2009) 2.18
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology (2012) 2.07
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol (2005) 2.06
Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol (2012) 2.05
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Type 2 diabetes and cardiovascular disease in South Asians. Prim Care Diabetes (2010) 1.78
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res (2011) 1.78
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 1.77
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol (2004) 1.70
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol (2009) 1.67
Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) (2009) 1.65
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Sexual network structure among a household sample of urban african american adolescents in an endemic sexually transmitted infection setting. Sex Transm Dis (2009) 1.61
Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol (2008) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart (2011) 1.56
Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat (2011) 1.55
Qualitative research contribution to a randomized clinical trial. Res Nurs Health (2005) 1.54
Short-term hemodynamic effects of cardiac resynchronization therapy in patients with heart failure, a narrow QRS duration, and no dyssynchrony. Circulation (2009) 1.51
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer (2004) 1.50
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat (2015) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology (2007) 1.38
Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist (2004) 1.37
Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol (2006) 1.34
Socioeconomic status in relation to early menarche among black and white girls. Cancer Causes Control (2008) 1.34
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res (2004) 1.33
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Antiemesis. J Natl Compr Canc Netw (2012) 1.28
Causes of physician delay in the diagnosis of breast cancer. Arch Intern Med (2002) 1.27
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A (2009) 1.27
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res (2012) 1.26
Cancer-related fatigue. J Natl Compr Canc Netw (2010) 1.26
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
Putting cancer pain management regimens into practice at home. J Pain Symptom Manage (2002) 1.22
Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res (2011) 1.22
Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab (2002) 1.21
Integrative Oncology Practice Guidelines. J Soc Integr Oncol (2007) 1.21
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer (2009) 1.20
Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res (2004) 1.20
Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol (2002) 1.19
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Does partner selection contribute to sex differences in sexually transmitted infection rates among African American adolescents in San Francisco? Sex Transm Dis (2006) 1.16
Isotope ratios of H, C, and O in CO2 and H2O of the martian atmosphere. Science (2013) 1.15
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat (2012) 1.15
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat (2010) 1.14
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res (2012) 1.14
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res (2012) 1.12
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer (2013) 1.11
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol (2008) 1.11